Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$3.1 - $9.02 $4,575 - $13,313
-1,476 Reduced 57.14%
1,107 $3,000
Q4 2022

Jun 14, 2023

BUY
$5.42 - $10.24 $7,999 - $15,114
1,476 Added 133.33%
2,583 $15.2 Million
Q3 2022

Jun 14, 2023

BUY
$8.03 - $12.77 $11,852 - $18,848
1,476 Added 133.33%
2,583 $22.7 Million
Q2 2022

Jun 20, 2023

BUY
$5.06 - $26.46 $7,468 - $39,054
1,476 Added 133.33%
2,583 $19,000
Q1 2022

Jun 20, 2023

BUY
$19.99 - $33.23 $29,505 - $49,047
1,476 Added 133.33%
2,583 $62,000
Q1 2022

Mar 30, 2023

SELL
$19.99 - $33.23 $155,762 - $258,928
-7,792 Reduced 75.1%
2,583 $62,000
Q1 2022

May 12, 2022

SELL
$19.99 - $33.23 $155,762 - $258,928
-7,792 Reduced 75.1%
2,583 $63,000
Q4 2021

Jun 21, 2023

BUY
$29.39 - $46.86 $272,386 - $434,298
9,268 Added 837.22%
10,375 $334,000
Q3 2021

Jun 21, 2023

BUY
$35.91 - $50.5 $332,813 - $468,034
9,268 Added 837.22%
10,375 $463,000
Q3 2021

Mar 30, 2023

BUY
$35.91 - $50.5 $6,356 - $8,938
177 Added 1.74%
10,375 $463,000
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $6,356 - $8,938
177 Added 1.74%
10,375 $464,000
Q2 2021

Jun 21, 2023

BUY
$30.39 - $42.18 $276,275 - $383,458
9,091 Added 821.23%
10,198 $385,000
Q2 2021

Mar 30, 2023

BUY
$30.39 - $42.18 $196,349 - $272,524
6,461 Added 172.89%
10,198 $385,000
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $309,795 - $429,982
10,194 Added 254850.0%
10,198 $386,000
Q1 2021

Jun 26, 2023

BUY
$31.96 - $46.5 $84,054 - $122,295
2,630 Added 237.58%
3,737 $138 Million
Q1 2021

May 14, 2021

SELL
$31.96 - $46.5 $119,306 - $173,584
-3,733 Reduced 99.89%
4 $138,000
Q4 2020

Jun 22, 2023

BUY
$22.8 - $37.05 $59,964 - $97,441
2,630 Added 237.58%
3,737 $123,000
Q4 2020

Mar 30, 2023

BUY
$22.8 - $37.05 $26,311 - $42,755
1,154 Added 44.68%
3,737 $123,000
Q4 2020

Feb 16, 2021

BUY
$22.8 - $37.05 $85,203 - $138,455
3,737 New
3,737 $124,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $293M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.